Clinical development of new drug-radiotherapy combinations.
View/ Open
Date
2016-10-01Author
Sharma, RA
Plummer, R
Stock, JK
Greenhalgh, TA
Ataman, O
Kelly, S
Clay, R
Adams, RA
Baird, RD
Billingham, L
Brown, SR
Buckland, S
Bulbeck, H
Chalmers, AJ
Clack, G
Cranston, AN
Damstrup, L
Ferraldeschi, R
Forster, MD
Golec, J
Hagan, RM
Hall, E
Hanauske, A-R
Harrington, KJ
Haswell, T
Hawkins, MA
Illidge, T
Jones, H
Kennedy, AS
McDonald, F
Melcher, T
O'Connor, JPB
Pollard, JR
Saunders, MP
Sebag-Montefiore, D
Smitt, M
Staffurth, J
Stratford, IJ
Wedge, SR
NCRI CTRad Academia-Pharma Joint Working Group,
Type
Journal Article
Metadata
Show full item recordAbstract
In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.
Collections
Subject
NCRI CTRad Academia-Pharma Joint Working Group
Humans
Neoplasms
Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
Combined Modality Therapy
Drug Approval
Radiation Dosage
Cell Hypoxia
Radiation Tolerance
Patient Participation
Quality of Health Care
Quality Assurance, Health Care
Clinical Trials as Topic
Patient Education as Topic
Research team
ICR-CTSU Urology and Head and Neck Trials Team
Quantitative Biomedical Imaging
Targeted Therapy
Language
eng
Date accepted
2016-05-15
License start date
2016-10
Citation
Nature reviews. Clinical oncology, 2016, 13 (10), pp. 627 - 642
Publisher
NATURE PUBLISHING GROUP